Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.59 |
| ▸ | HTR2A | P28223 | 5/20 | 0.50 |
| ▸ | HTR2C | P28335 | 5/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 12/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13403405 | 0.84 | NOTUM (0.47) | NOTUMHTR2AHTR2CHTR1ASIGMAR1 | |
| SCHEMBL19930594 | 0.81 | HTR2A (0.53) | NOTUMHTR2AHTR2CHTR1ASIGMAR1 | |
| SCHEMBL20080086 | 0.79 | HTR2A (0.50) | NOTUMHTR2AHTR2CHTR1ASIGMAR1 | |
| SCHEMBL17907965 | 0.78 | HTR2A (0.48) | NOTUMHTR2AHTR2C | |
| SCHEMBL17907930 | 0.78 | HTR2A (0.48) | NOTUMHTR2AHTR2C | |
| SCHEMBL13279280 | 0.78 | SIGMAR1 (0.42) | NOTUMHTR2AHTR2CSIGMAR1 | |
| SCHEMBL17907932 | 0.78 | SIGMAR1 (0.41) | NOTUMHTR2AHTR2CSIGMAR1 | |
| SCHEMBL30684257 | 0.77 | HTR2A (0.56) | NOTUMHTR2AHTR2CHTR1ASIGMAR1 | |
| SCHEMBL10735669 | 0.77 | HTR2A (0.56) | NOTUMHTR2AHTR2CHTR1ASIGMAR1 | |
| SCHEMBL18911621 | 0.75 | HTR2A (0.73) | NOTUMHTR2AHTR2CHTR1ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11524958-B2 | Tricyclic compound as CRTH2 inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-12-13 | — | — | US | disclosed |
| US-20210403466-A1 | TRICYCLIC COMPUND AS CRTH2 INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2021-12-30 | — | — | US | disclosed |
| US-20210323976-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. | 2021-10-21 | — | — | US | disclosed |
| US-20210323976-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. | 2021-10-21 | — | — | US | disclosed |
| CN-107973791-B | Fused or tricyclic aryl pyrimidine compounds as kinase inhibitors | 南京圣和药业股份有限公司 | 2020-04-07 | — | — | CN | disclosed |
| CN-107614503-B | Fused or tricyclic aryl pyrimidine compounds as kinase inhibitors | 广东众生药业股份有限公司 | 2020-03-10 | — | — | CN | disclosed |
| EP-3290419-B1 | FUSED-RING OR TRICYCLIC ARYL PYRIMIDINE COMPOUND USED AS KINASE INHIBITOR | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO LTD (CN) | 2019-08-07 | — | — | EP | disclosed |
| EP-3290419-B1 | FUSED-RING OR TRICYCLIC ARYL PYRIMIDINE COMPOUND USED AS KINASE INHIBITOR | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO LTD (CN) | 2019-08-07 | — | — | EP | disclosed |
| EP-3312179-B1 | FUSED-RING OR TRICYCLIC ARYL PYRIMIDINE COMPOUND USED AS KINASE INHIBITOR | NANJING SANHOME PHARMACEUTICAL CO LTD (CN) | 2019-07-10 | — | — | EP | disclosed |
| EP-3312179-B1 | FUSED-RING OR TRICYCLIC ARYL PYRIMIDINE COMPOUND USED AS KINASE INHIBITOR | NANJING SANHOME PHARMACEUTICAL CO LTD (CN) | 2019-07-10 | — | — | EP | disclosed |
| US-7696222-B2 | Indole derivatives as CRTH2 receptor antagonists | MERCK FROSST CANADA LTD (CA) | 2010-04-13 | — | — | US | disclosed |
| WO-2010031182-A1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | MERCK FROSST CANADA LTD. (CA) | 2010-03-25 | — | — | WO | disclosed |
| US-20090286825-A1 | Indole derivatives as crth2 receptor antagonists | MERCK CANADA INC. (CA) | 2009-11-19 | — | — | US | disclosed |
| US-20090286825-A1 | Indole derivatives as crth2 receptor antagonists | MERCK CANADA INC. (CA) | 2009-11-19 | — | — | US | disclosed |
| EP-1915372-A1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | Merck Frosst Canada Ltd. (CA) | 2008-04-30 | — | — | EP | disclosed |
| WO-2007019675-A1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | MERCK FROSST CANADA LTD. (CA) | 2007-02-22 | — | — | WO | disclosed |
| EP-0470490-B1 | Substituted pyrroles | HOFFMANN LA ROCHE (CH) | 1999-05-06 | — | — | EP | disclosed |
| EP-0384349-B1 | Substituted pyrroles | HOFFMANN LA ROCHE (CH) | 1994-04-27 | — | — | EP | disclosed |
| US-5292747-A | Substituted pyrroles | HOFFMAN-LA ROCHE INC. (US) | 1994-03-08 | — | — | US | disclosed |
| EP-0470490-A1 | Substituted pyrroles | F. HOFFMANN-LA ROCHE AG (CH) | 1992-02-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286825-A1 | Indole derivatives as crth2 receptor antagonists | MC2R, HRH2, PTGDR | NOTUM 4041/4885HTR2A 154/4885HTR2C 236/4885 |
| US-20210403466-A1 | TRICYCLIC COMPUND AS CRTH2 INHIBITOR | NR3C2, CRHR2, CRHR1 | NOTUM 3876/4885HTR2A 604/4885HTR2C 749/4885 |
| US-11524958-B2 | Tricyclic compound as CRTH2 inhibitor | NR1H2, NR3C2, NR1H4 | NOTUM 3644/4885HTR2A 772/4885HTR2C 1011/4885 |
| US-20210323976-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ERBB2, EGFR, ERBB3 | NOTUM 2272/4885HTR2A 1012/4885HTR2C 642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.